Granted Patent
B2
US 12,295,640 · App. 17/101,434 · Granted May 13, 2025
Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
Assignee:
ImmunSys, Inc.
A61B18/14A61B5/14532A61B5/14539A61B5/14546A61B5/4839A61B5/4848A61B18/1477A61M5/00A61N1/325A61N1/327A61B2017/00061A61B2017/00159A61B2018/00577A61B2018/00732A61B2018/00821A61B2018/00875A61B2018/126A61M2202/097A61M2205/054
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method of non-thermally ablating undesirable tissue in the body by application of pulsed, bipolar, instant charge reversal electrical fields of sufficient energy to cause complete and immediate cell membrane rupture and destruction. Energy is delivered through radio frequency pulses of particular frequencies, wave characteristics, pulse widths and pulse numbers, such that enhanced physical stresses are placed on the cell membrane to cause its immediate and complete destruction thereby spilling the entire cell content and membrane constituents into, the extracellular space without denaturing proteins so as to enable an immunological response to destroy and remove the target tissue and similarly marked tissue elsewhere in the subject.
Claims (17)
1. A method of treating a tumor in a patient, the method comprising:
ablating the tumor, including applying an energy to the tumor sufficient to cause destruction of a cell membrane of cells of the tumor and spillage of intracellular components and antigens into an extracellular space; and
administering to the patient intratumorally a composition comprising a combination of at least two immune checkpoint inhibitors and an immunomodulatory agent, each being present in a therapeutically effective amount, wherein the at least two immune checkpoint inhibitors are a CTLA-4 inhibitor and a PD-1 inhibitor.
2. The method of claim 1 in which ablating the tumor comprises ablating the tumor using a non-heat producing ablation modality.
3. The method of claim 1 , in which ablating the tumor causes exposure of non denatured intra-cellular and membrane proteins.
4. The method of claim 1 , in which ablating the tumor causes immediate spillage of the intracellular components and antigens into the extracellular space.
5. The method of claim 1 , in which applying an energy to the tumor comprises applying an electric field to the tumor.
6. The method of claim 5 , in which applying an electric field to the tumor comprises applying an electric field in a range of 1,500 V/cm to 10,000 V/cm.
7. The method of claim 5 , in which applying an electric field to the tumor comprises applying an electric field having a frequency of between 14.2 kHz and 500 kHz.
8. The method of claim 5 , in which the frequency of the electric field is between 100 kHz and 450 kHz.
9. The method of claim 1 , in which applying a field to the tumor comprises delivering, to an electrode inserted into the tumor, a series of bipolar electric pulses characterized by an instant charge reversal between a positive and a negative polarity.
10. The method of claim 9 , in which a voltage of the series of bipolar electric pulses is between 0.5 kV to 10 kV.
11. The method of claim 9 , in which each pulse has a duration of between 100 μs and 1000 μs.
12. The method of claim 1 , comprising administering the composition after application of the energy to the tumor.
13. The method of claim 1 , comprising determining an amount of energy to apply to the tumor based on a tissue type of the tumor.
14. The method of claim 1 , in which the immunomodulatory agent comprises an agent capable of modulating myeloid cell functions.
15. The method of claim 14 , in which the immunomodulatory agent comprises Tasquinimod.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2024
From: ONIK, GARY M.; MIESSAU, JAMES A.
To: RFEMB HOLDINGS, LLC
Reel/Frame 069466/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2024
From: RFEMB HOLDINGS, LLC
To: IMMUNSYS, INC.
Reel/Frame 069467/0406 →
SECURITY INTEREST
Recorded Jun 14, 2023
From: IMMUNSYS, INC.
To: PHOENIX IMMUNO, LLC
Reel/Frame 063949/0493 →
Continuity (4)
Continuation
15102120
Provisional Application
61912172
· Dec 5, 2013
References Cited (397)
US 4483338A
· Bloom
· 1984
[cited by applicant]
US 5139496A
· Hed et al.
· 1992
[cited by applicant]
US 5575811A
· Reid
· 1996
[cited by applicant]
US 5672174A
· Gough et al.
· 1997
[cited by applicant]
US 5931807A
· McClure
· 1999
[cited by applicant]
US 6120493A
· Hofmann
· 2000
[cited by applicant]
US 6135990A
· Heller et al.
· 2000
[cited by applicant]
US 6214297B1
· Zhang et al.
· 2001
[cited by applicant]
US 6241702B1
· Lundquist
· 2001
[cited by applicant]
US 6379348B1
· Onik
· 2002
[cited by applicant]
US 6408199B1
· Goldin
· 2002
[cited by applicant]
US 6482619B1
· Rubisky et al.
· 2002
[cited by applicant]
US 6505629B1
· Mikus et al.
· 2003
[cited by applicant]
US 6575969B1
· Rittman, III et al.
· 2003
[cited by applicant]
US 6623480B1
· Kuo et al.
· 2003
[cited by applicant]
US 6733485B1
· Whitehurst et al.
· 2004
[cited by applicant]
US 6978174B2
· Gelfand et al.
· 2005
[cited by applicant]
US 7113821B1
· Sun et al.
· 2006
[cited by applicant]
US 7162303B2
· Levin et al.
· 2007
[cited by applicant]
US 7572623B2
· Mangano et al.
· 2009
[cited by applicant]
US 7620451B2
· Demarais et al.
· 2009
[cited by applicant]
US 7653438B2
· Deem et al.
· 2010
[cited by applicant]
US 7680543B2
· Azure
· 2010
[cited by applicant]
US 7744878B2
· Mather
· 2010
[cited by applicant]
US 7853333B2
· Demarais
· 2010
[cited by applicant]
US 7937143B2
· Demarais et al.
· 2011
[cited by applicant]
US 7938824B2
· Chomenky
· 2011
[cited by applicant]
US 8048067B2
· Davalos et al.
· 2011
[cited by applicant]
US 8114070B2
· Rubinsky et al.
· 2012
[cited by applicant]
US 8131371B2
· Demarais et al.
· 2012
[cited by applicant]
US 8145316B2
· Deem et al.
· 2012
[cited by applicant]
US 8221411B2
· Francischelli et al.
· 2012
[cited by applicant]
US 8226648B2
· Paul et al.
· 2012
[cited by applicant]
US 8231603B2
· Hobbs et al.
· 2012
[cited by applicant]
US 8282631B2
· Davalos et al.
· 2012
[cited by applicant]
US 8465484B2
· Davalos et al.
· 2013
[cited by applicant]
US 8814860B2
· Davalos et al.
· 2014
[cited by applicant]
US 9545523B2
· Nanda
· 2017
[cited by applicant]
US 9598491B2
· Ahmed et al.
· 2017
[cited by applicant]
US 20010044596A1
· Jaafar
· 2001
[cited by applicant]
US 20020019644A1
· Hastings et al.
· 2002
[cited by applicant]
US 20020086014A1
· Korman
· 2002
[cited by examiner]
US 20020087151A1
· Mody et al.
· 2002
[cited by applicant]
US 20020095124A1
· Palasis et al.
· 2002
[cited by applicant]
US 20020111617A1
· Cosman et al.
· 2002
[cited by applicant]
US 20020128640A1
· Swanson et al.
· 2002
[cited by applicant]
US 20020183684A1
· Dev et al.
· 2002
[cited by applicant]
US 20020193784A1
· McHale et al.
· 2002
[cited by applicant]
US 20020193789A1
· Underwood et al.
· 2002
[cited by applicant]
US 20020193833A1
· Dimmer et al.
· 2002
[cited by applicant]
US 20030018329A1
· Hooven
· 2003
[cited by applicant]
US 20030045495A1
· Li et al.
· 2003
[cited by applicant]
US 20030055471A1
· Fenn
· 2003
[cited by examiner]
US 20030093067A1
· Panescu
· 2003
[cited by applicant]
US 20030153960A1
· Chornenky
· 2003
[cited by applicant]
US 20030163040A1
· Gildenberg
· 2003
[cited by applicant]
US 20030204161A1
· Ferek-Petric
· 2003
[cited by applicant]
US 20030216722A1
· Swanson et al.
· 2003
[cited by applicant]
US 20030216792A1
· Levin et al.
· 2003
[cited by applicant]
US 20040143261A1
· Hartley et al.
· 2004
[cited by applicant]
US 20040248842A1
· Wagner et al.
· 2004
[cited by applicant]
US 20050038422A1
· Maurice et al.
· 2005
[cited by applicant]
US 20050182462A1
· Chomenky et al.
· 2005
[cited by applicant]
US 20050214268A1
· Cavanagh et al.
· 2005
[cited by applicant]
US 20050221270A1
· Connelly et al.
· 2005
[cited by applicant]
US 20050261672A1
· Deem
· 2005
[cited by applicant]
US 20050288667A1
· Thompson et al.
· 2005
[cited by applicant]
US 20050288730A1
· Deem et al.
· 2005
[cited by applicant]
US 20060041277A1
· Deem et al.
· 2006
[cited by applicant]
US 20060073589A1
· Belardelli et al.
· 2006
[cited by applicant]
US 20060161246A1
· Rhim et al.
· 2006
[cited by applicant]
US 20060293725A1
· Rubinsky et al.
· 2006
[cited by applicant]
US 20060293730A1
· Rubinsky et al.
· 2006
[cited by applicant]
US 20070031338A1
· Zabinski
· 2007
[cited by applicant]
US 20070043345A1
· Davalos et al.
· 2007
[cited by applicant]
US 20070049919A1
· Lee
· 2007
[cited by applicant]
US 20070060989A1
· Deem
· 2007
[cited by applicant]
US 20070066957A1
· Demarais et al.
· 2007
[cited by applicant]
US 20070083239A1
· Demarais et al.
· 2007
[cited by applicant]
US 20070129720A1
· Demarais et al.
· 2007
[cited by applicant]
US 20070233057A1
· Konishi
· 2007
[cited by applicant]
US 20080033417A1
· Nields et al.
· 2008
[cited by applicant]
US 20080058706A1
· Zhang et al.
· 2008
[cited by applicant]
US 20080071265A1
· Azure
· 2008
[cited by applicant]
US 20080132884A1
· Rubinsky et al.
· 2008
[cited by applicant]
US 20080132885A1
· Rubinsky et al.
· 2008
[cited by applicant]
US 20080208052A1
· LePivert et al.
· 2008
[cited by applicant]
US 20080247506A1
· Maschke
· 2008
[cited by applicant]
US 20080306476A1
· Hennings et al.
· 2008
[cited by applicant]
US 20080319375A1
· Hardy
· 2008
[cited by applicant]
US 20090028857A1
· Li et al.
· 2009
[cited by applicant]
US 20090088648A1
· Jaffe et al.
· 2009
[cited by applicant]
US 20090143717A1
· Bass
· 2009
[cited by applicant]
US 20090177094A1
· Brown et al.
· 2009
[cited by applicant]
US 20090292342A1
· Rubinsky et al.
· 2009
[cited by applicant]
US 20090326366A1
· Krieg
· 2009
[cited by applicant]
US 20100023004A1
· Francischelli et al.
· 2010
[cited by applicant]
US 20100069833A1
· Wenderow et al.
· 2010
[cited by applicant]
US 20100152725A1
· Pearson et al.
· 2010
[cited by applicant]
US 20100179530A1
· Long et al.
· 2010
[cited by applicant]
US 20100221351A1
· He et al.
· 2010
[cited by applicant]
US 20100249771A1
· Pearson et al.
· 2010
[cited by applicant]
US 20100250209A1
· Pearson et al.
· 2010
[cited by applicant]
US 20100331758A1
· Davalos et al.
· 2010
[cited by applicant]
US 20110082534A1
· Wallace
· 2011
[cited by applicant]
US 20110112520A1
· Michael
· 2011
[cited by applicant]
US 20110160514A1
· Long et al.
· 2011
[cited by applicant]
US 20110160614A1
· Fujiwara et al.
· 2011
[cited by applicant]
US 20110166499A1
· Demarais et al.
· 2011
[cited by applicant]
US 20110190764A1
· Long et al.
· 2011
[cited by applicant]
US 20110217270A1
· Cavanaugh, III et al.
· 2011
[cited by applicant]
US 20120021481A1
· Hebner et al.
· 2012
[cited by applicant]
US 20120071872A1
· Rubinsky et al.
· 2012
[cited by applicant]
US 20120071874A1
· Davalos et al.
· 2012
[cited by applicant]
US 20120143181A1
· Demarais et al.
· 2012
[cited by applicant]
US 20120252087A1
· Hebner et al.
· 2012
[cited by applicant]
US 20120253188A1
· Holland
· 2012
[cited by applicant]
US 20120277763A1
· Greenblatt
· 2012
[cited by applicant]
US 20130108667A1
· Wang et al.
· 2013
[cited by applicant]
US 20130211230A1
· Sperling
· 2013
[cited by applicant]
US 20130289369A1
· Margolis
· 2013
[cited by applicant]
US 20130302409A1
· Fuchs et al.
· 2013
[cited by applicant]
US 20140012251A1
· Himmelstein et al.
· 2014
[cited by applicant]
US 20140088578A1
· Rubinsky et al.
· 2014
[cited by applicant]
US 20140205609A1
· Valentine
· 2014
[cited by applicant]
US 20140356397A1
· Akle et al.
· 2014
[cited by applicant]
US 20150190505A1
· Yeung
· 2015
[cited by applicant]
US 20150201996A1
· Rubisky
· 2015
[cited by applicant]
US 20150265705A1
· Li et al.
· 2015
[cited by applicant]
US 20150352135A1
· Paya Cuenca
· 2015
[cited by examiner]
US 20160128767A1
· Azamian et al.
· 2016
[cited by applicant]
US 20160338754A1
· Baust et al.
· 2016
[cited by applicant]
US 20160346354A1
· Heslet et al.
· 2016
[cited by applicant]
US 20170274011A1
· Garibyan et al.
· 2017
[cited by applicant]
US 20180021084A1
· Onik et al.
· 2018
[cited by applicant]
US 20180028260A1
· Onik et al.
· 2018
[cited by applicant]
US 20180028267A1
· Onik et al.
· 2018
[cited by applicant]
US 20180154142A1
· Guo et al.
· 2018
[cited by applicant]
US 20180318365A1
· Yeung et al.
· 2018
[cited by applicant]
US 20190183561A1
· Hobbs et al.
· 2019
[cited by applicant]
US 20190209652A1
· Pierce et al.
· 2019
[cited by applicant]
US 20190241658A1
· Frederick
· 2019
[cited by applicant]
US 20200277379A1
· Bostwick et al.
· 2020
[cited by applicant]
US 20220265343A1
· Onik et al.
· 2022
[cited by applicant]
US 20240058049A1
· Onik et al.
· 2024
[cited by applicant]
US 20240156513A1
· Onik
· 2024
[cited by examiner]
CN 1280513A
· 2001
[cited by applicant]
CN 1658924A
· 2005
[cited by applicant]
CN 101085391A
· 2007
[cited by applicant]
CN 103118678
· 2013
[cited by applicant]
CN 104024276A1
· 2014
[cited by applicant]
JP 2001523987
· 2001
[cited by applicant]
JP 2006187446
· 2006
[cited by applicant]
JP 2009297527
· 2009
[cited by applicant]
JP 2010500153
· 2010
[cited by applicant]
JP 2013531043
· 2013
[cited by applicant]
JP 5341287B2
· 2013
[cited by applicant]
JP 201538492A
· 2015
[cited by applicant]
WO WO2004037313
· 2004
[cited by applicant]
WO WO2008034103
· 2008
[cited by applicant]
WO WO2010080974
· 2010
[cited by applicant]
WO WO2012088149
· 2012
[cited by applicant]
WO WO2012099974
· 2012
[cited by applicant]
WO WO2013053775
· 2013
[cited by applicant]
WO WO2013079980
· 2013
[cited by applicant]
WO WO2014149690
· 2014
[cited by applicant]
WO WO2015085162
· 2015
[cited by applicant]
WO WO2015125159
· 2015
[cited by applicant]
WO WO2015140150
· 2015
[cited by applicant]
WO WO2015153639
· 2015
[cited by applicant]
WO WO2016123608
· 2016
[cited by applicant]
WO WO2016126778
· 2016
[cited by applicant]
WO WO2016126811
· 2016
[cited by applicant]
WO WO2016126905
· 2016
[cited by applicant]
WO WO2016127162
· 2016
[cited by applicant]
WO WO2017123981
· 2017
[cited by applicant]
Aarts et al., “Cryoablation and immunotherapy: an overview of evidence on its synergy,” Insights Into Imaging, Dec. 2019, 10(1), 12 pages.
[cited by applicant]
Abdo et al., “Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers,” Frontiers in Oncology, Mar. 28, 2018, 8:85.
[cited by applicant]
AMGen.com, “FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US,” retrieved Aug. 13, 2020 from URL <https://www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimoge…
[cited by applicant]
Arora et al., “Neoadjuvant Intratumoral Cytokine-Loaded Microspheres are Superior to Postoperative Autologous Cellular Vaccines in Generating Systematic Anti-Tumor Immunity,” Journal of Surgical Oncology 94(5):403-412, …
[cited by applicant]
Bastianpillai et al., “Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment,” Tumor Biology, Dec. 1, 2015, 36(12):9137-46.
[cited by applicant]
Brooks et al., “Intratumoral injection of GM-CSF in perspective—A review,” Journal of Medicine. Jan. 1, 2003, 34(1-6):149-53.
[cited by applicant]
Bulvik et al., “Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model,” Radiology, Aug. 2016, 280(2):413-24.
[cited by applicant]
Chang et al., “Blocking of the PD-I/PD-LI Interaction by ad-Peptide Antagonist for Cancer Immunotherapy,” Angewandte Chemie International Edition, Sep. 28, 2015, 54(40):11760-4.
[cited by applicant]
EP Extended Search Report in European Appln. No. 17739066.3, dated Dec. 16, 2019, 20 pages.
[cited by applicant]
EP Search Report in European Appln. No. 17739066.3, dated Dec. 17, 2019, 20 pages.
[cited by applicant]
EP European Search Report in European U.S. Appl. No. 17739066, dated Aug. 13, 2019, 23 pages.
[cited by applicant]
Fehres et al.,. “Understanding the biology of antigen cross-presentation for the design of vaccines against cancer,” Frontiers in immunology. Apr. 8, 2014, 5:149.
[cited by applicant]
Fehres et al., “Understanding the Biology of Antigen Cross-Presentation for the Design of Vaccines Against Cancer,” Frontiers in Immunology, Apr. 8, 2014, 5(149):1-10.
[cited by applicant]
Hebb et al., “Systemic Antitumor Effects of Intratumoral Administration of the Novel Immunotherapeutic Combination Anti-CTLA4, Anti-CD137, and Anti-0X40 in Mouse Models of Lymphoma and Solid Tumor,” Blood Journal, Dec. …
[cited by applicant]
Ito et al., “Immune adjuvant activity of pre-resectional radiofrequency ablation protects against local and systemic recurrence in aggressive murine colorectal cancer,” PLoS One, Nov. 23, 2015, 10(11):e0143370, 23 pages.
[cited by applicant]
Jonathan et al., “Systemic Antitumor Effects of Intratumoral Administration of the Novel Immunotherapeutic Combination Anti-CTLA4, Anti-CD137, and Anti-OX40 in Mouse Models of Lymphoma and Solid Tumor,” Blood, Jan. 1, 2…
[cited by applicant]
Koster et al., “Recent developments and future challenges in immune checkpoint inhibitory cancer treatment,” Current opinion in oncology, Nov. 1, 2015, 27(6):482-8.
[cited by applicant]
Koster et el., “Recent developments and future challenges in immune checkpoint inhibitory cancer treatment,” Curr Opin Oncol., Nov. 2015, 27(6):482-488.
[cited by applicant]
Immuno-Oncology News.com, “Cryoablation Combined With Intra-tumoral Injection of Immunotherapeutic Drugs Offers Promising Outcomes,” Feb. 10, 2015, 2 pages.
[cited by applicant]
Machlenkin et al., “Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity,” Clinical Cancer Research, Jul. 1, 2005, 11(13):4955-61.
[cited by applicant]
Marabelle et al., “Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity,” Clinical Cancer Research, Oct. 1, 2013, 19(19):5261, 4 pages.
[cited by applicant]
Marabelle et al., “Intratumoral immunization: a new paradigm for cancer therapy,” Clinical Cancer Research, Apr. 1, 2014, 20(7):1747-56.
[cited by applicant]
Marabelle et al., “Intratumoral immunotherapy: using the tumor as the remedy,” Annals of Oncology, Dec. 1, 2017, 28:xii33-43, 11 pages.
[cited by applicant]
Marabelle et al., “Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT),” Annals of Oncology, Nov. 1, 2018, 29(11):2163-74.
[cited by applicant]
Mizukoshi et al., “Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma,” Hepatology, Apr. 2013, 57(4):1448-57.
[cited by applicant]
Paiella et al., “Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation); a review,” Gastroenterology Research and Practice, Oct. 2016, vol. 2016, 10 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2017/013486, dated Jul. 17, 2018, 33 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2017/013486, dated May 19, 2017, 38 pages.
[cited by applicant]
Rosenberg et al., “Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors,” Journal for Immuno Therapy of Cancer, Dec. 2015, 3(2):1-4.
[cited by applicant]
Shi et al., “PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor,” Clinical Cancer Research, Mar. 1, 2016, 22(5):1173-84.
[cited by applicant]
Sidana, “Cancer immunotherapy using tumor cryoablation,” Immunotherapy, Jan. 2014, 6(1):85-93.
[cited by applicant]
Somasundaram et al., “Nivolumab in Combination with Ipilimumab for the Treatment of Melanoma. Expert Review of Anti-Cancer Therapy,” 15(10):1-13, dated Oct. 2015.
[cited by applicant]
Waitz et al., “CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection,” Oncoimmunology, Jul. 1, 2012, 1(4):544-6.
[cited by applicant]
Wang et al., “In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates,” Cancer Immunology Research 2(9):846-856, dated May 28, 2014.
[cited by applicant]
Woolley et al., “Effect of Freezing Parameters (Freeze Cycle and Thaw Process) on Tissue Destruction Following Renal Cryoablation,” Journal of Endourology 16(7):519-522, dated Sep. 2002.
[cited by applicant]
Yu et al., “Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death,” Oncotarget, Aug. 2014, 5(15):6526-39.
[cited by applicant]
Zhou et al., “Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors,” Cell, Jun. 4, 2015, 161(6):1280-92.
[cited by applicant]
Al Sakere et al., “A study of the immunological response to tumor ablation with irreversible electroporation,” Technol Cancer Res Treat., Aug. 2007, 6(4):301-306.
[cited by applicant]
Ammar et al., “Impact of a pulsed electric field on damage of plant tissues: effects of cell size and tissue electrical conductivity,” J Food Sci., Jan.-Feb. 2011, 76(1):E90-7.
[cited by applicant]
Arena et al. “High-Frequency Irreversible Electroporation (H-FIRE) for Non-Thermal Ablation without Muscle Contraction”, Biomed Eng. Online Nov. 21, 2011, 10:102.
[cited by applicant]
Aronsson et al., “Inactivation of
[cited by applicant]
Asavasanti et al., “Critical electric field strengths of onion tissues treated by pulsed electric fields,” J Food Sci., Sep. 2010, 75(7):E433-43.
[cited by applicant]
Asavasanti et al., “Permeabilization of plant tissues by monopolar pulsed electric fields: effect of frequency,” J Food Sci. Jan.-Feb. 2011, 76(1):E98-111.
[cited by applicant]
Au et al., “Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response,” Surgery, Sep. 2013, 154(3):496-503.
[cited by applicant]
AU Office Action in Australian Appln. No. 2020200688, dated Jun. 18, 2020, 5 pages.
[cited by applicant]
Barnett et al., “Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis,” The Journal of thoracic and cardiovascular surgery, May 1, 2006, 131(5):1029-35.
[cited by applicant]
Beebe et al., “Non-ionizing radiation with nanosecond pulsed electric fields as a cancer treatment: in vitro studies,” Conf Proc IEEE Eng Med Biol Soc., Sep. 2-6, 2009, pp. 6509-6512.
[cited by applicant]
Bertacchini et al., “Design of an irreversible electroporation system for clinical use,” Technol Cancer Res Treat., Aug. 2007, 6(4):313-20.
[cited by applicant]
Chang et al. “Changes in Membrane Structure Induced by Electroporation as Revealed by Rapid-Freezing Electron Microscopy”, Biophys J., Jul. 1, 1990, 58(1):1-12.
[cited by applicant]
Chang et al., “Construction of a Genomic Map of H. pylori by Pulsed-Field Gel Electrophoresis (PFGE).” Methods Mol Med., 1997. 8:165-176.
[cited by applicant]
Chen et al., “Leukemic cell intracellular responses to nanosecond electric fields,” Biochem Biophys Res Commun., Apr. 30, 2004, 317(2):421-427.
[cited by applicant]
Chen et al., “Membrane electroporation theories: a review,” Med Biol Eng Comput., 2006, 44:5-14.
[cited by applicant]
Chen et al., “Nanosecond electric pulses penetrate the nucleus and enhance speckle formation,” Biochem Biophys Res Commun., Dec. 14, 2007, 364(2):220-225.
[cited by applicant]
Chen et al., “Picosecond pulsed electric fields induce apoptosis in HeLa cells via the endoplasmic reticulum stress and caspase-dependent signaling pathways,” Int J Oncol., Mar. 2013, 42(3):963-70.
[cited by applicant]
Cox et al.,. “The surgical treatment of atrial fibrillation,” The Journal of thoracic and cardiovascular surgery. 1991, 101(1-4):402-426, 569-592.
[cited by applicant]
Crowley “Electrical breakdown of bimolecular lipid membranes as an electromechanical instability,” Biophys J., Jul. 1973, 13(7):711-724.
[cited by applicant]
Cummings et al., “Alternative energy sources for the ablation of arrhythmias,” Pacing and clinical electrophysiology, May 2005, 28(5):434-43.
[cited by applicant]
Djunzenova et al., “Effect of electric field pulses on the viability and on the membrane-bound immunoglobulins of LPS-activated murine B-lymphocytes: correlation with the cell cycle,” Cymetry, Jan. 1, 1994, 15(1):35-45.
[cited by applicant]
Doll et al., “Esophageal perforation during left atrial radiofrequency ablation: is the risk too high?,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 1, 2003, 125(4):836-42.
[cited by applicant]
Dortch et al., “Characterization of pulsed magnetic field therapy in a rat model for rheumatoid arthritis,” Biomed Sci Instrum., 2006, 42:302-307, Abstract Only.
[cited by applicant]
Dyson et al., “Kinetic and physical studies of cell death induced by chemotherapeutic agents or hyperthermia,” Cell Tissue Kinet., May 1986, 19(3):311-324.
[cited by applicant]
Eppich et al., “Pulsed electric fields for selection of hematopoietic cells and depletion of tumor cell contaminants,” Nat Biotechnol., Aug. 2000, 18(8):882-887.
[cited by applicant]
Ersus et al., “Disintegration efficiency of pulsed electric field induced effects on onion (
[cited by applicant]
European Search Report in European Application No. 16744266.4, dated Oct. 18, 2018, 10 pages.
[cited by applicant]
Foltz, “Algae Lysis with Pulsed Electric Fields,” California State Polytechnic University, San Luis Obispo 2012, [retrieved on May 13, 2019]retrieved from URL <http://digitalcommons.-calpoly.edu/theses/732/>, 76 pages.
[cited by applicant]
García et al., “Biosynthetic requirements for the repair of sublethal membrane damage in
[cited by applicant]
Garilevich et al., “Outlook for the use of focused shock waves and pulsed electric fields in the complex treatment of malignant neoplasms,” Conf Proc IEEE Eng Med Biol Soc. 2006, 1:6370-6372.
[cited by applicant]
Gómez-Ochoa et al., “Pulsed electromagnetic fields decrease proinflammatory cytokine secretion (IL-1β and TNF-α) on human fibroblast-like cell culture,” Rheumatol Int., Oct. 2011, 31(10):1283-1289.
[cited by applicant]
Gong et al., “Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen,” Neoplasia…
[cited by applicant]
Gordon et al., “Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations,” Med Hypotheses., Jan. 1979, 5(1):83-102.
[cited by applicant]
Grys et al., “Decreasing the thresholds for electroporation by sensitizing cells with local cationic anesthetics and substances that decrease the surface negative electric charge,” Cell Mol Biol Lett., Mar. 2014, 19(1):…
[cited by applicant]
Hamid et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” N Engl J Med., Jul. 11, 2013, 369(2):134-144.
[cited by applicant]
Harris “Effects of Tumor-like assay conditions, Ionizing radiation, and hyperthermia on immune lysis of tumor cells by cytotoxic T-lymphocytes,” Cancer Res., Aug. 1976, 36(8):2733-2739.
[cited by applicant]
Hillen et al., “Treatment of Metastatic Posterior Vertebral Body Osseous Tumors by Using a Targeted Bipolar Radiofrequency Ablation Device: Technical Note,” Radiology, Jun. 13, 2014, 273(1):261-267.
[cited by applicant]
Hua et al., “Intense picosecond pulsed electric fields induce apoptosis through a mitochondrial-mediated pathway in HeLa cells,” Mol Med Rep., Apr. 2012, 5(4):981-987.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2014/068774, dated Jun. 7, 2016, 13 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/015944, dated Aug. 1, 2017, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/016300, dated Aug. 8, 2017, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/016352, dated Aug. 8, 2017, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/016501, dated Aug. 8, 2017, 7 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2014/068774, dated Mar. 19, 2015, 15 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/015944, dated Jul. 29, 2016, 13 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/016300, dated Jul. 8, 2016, 9 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/016352, dated Jul. 18, 2016, 9 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/016501, dated Sep. 2, 2016, 10 pages.
[cited by applicant]
Iu et al., “Reduction in levels of
[cited by applicant]
Jaeger et al., “Protective effect of milk constituents and sublethal injuries limiting process effectiveness during PEF inactivation of Lb. rhamnosus,” Int J Food Microbiol., Aug. 31, 2009, 134(1-2):154-161.
[cited by applicant]
Jeffers et al., “Dimethylformamide as an enhancer of cavitation-induced cell lysis in vitro,” J Acoust Soc Am., Jan. 1995, 97(1):669-676.
[cited by applicant]
Jia et al., “Crystal structure of human grancalcin, a member of the penta-EF-hand protein family,” J Mol Biol., Jul. 28, 2000, 300(5):1271-81.
[cited by applicant]
JP Office action in Japanese Appln. No. 2016-536858, dated Nov. 12, 2019, 29 pages (with english translation).
[cited by applicant]
JP Office action in Japanese Appln. No. 2017-540247, dated Nov. 26, 2019, 27 pages (with english translation).
[cited by applicant]
Kawano et al., “Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma”, Clin Orthop Relat Res., May 2010, 468(5):1373-1383.
[cited by applicant]
Kennedy et al., “Cationic Peptide Exposure Enhances Pulsed-Electric-Field-Mediated Membrane Disruption,” PLoS One, Mar. 26, 2014, 9(3):e92528.
[cited by applicant]
Kennedy et al., “Quantification of electroporative uptake kinetics and electric field heterogeneity effects in cells,” Biophys J., Jun. 2008, 94(12):5018-5027.
[cited by applicant]
Kim et al., “Changes of apoptosis in tumor tissues with time after irreversible electroporation,” Biochem Biophys Res Commun., Jun. 14, 2013, 435(4):651-656.
[cited by applicant]
Koga et al., “Interstitial Radiofrequency Hyperthermia for Brain Tumors,” Neurol Med Chir., May 1993, 33(5):290-294.
[cited by applicant]
Laufer et al., “Tissue Characterization Using Electrical Impedance Spectroscopy Data: A Linear Algebra Approach, ” Physiol Measu., 2012, 33:997-1013.
[cited by applicant]
Lee et al., “Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes,” J Vasc Interv Radiol., Jan. 2012, 23(1):107-113.
[cited by applicant]
Li et al., “Immunologic Response to Tumor Ablation with Irreversible Electroporation”, PLOS One, Nov. 6, 2012, 7(11):e48749.
[cited by applicant]
Li et al., “The effect of lipid molecular packing stress on cationic liposome-induced rabbit erythrocyte fusion,” Biochim Biophys Acta., Jan. 14, 1997, 1323(1):105-116.
[cited by applicant]
Lin et al., “Preparation of antioxidant peptide from egg white protein and improvement of its activities assisted by high-intensity pulsed electric field,” J Sci Food Agric., May 2012, 92(7): 1554-1561.
[cited by applicant]
Ma et al., “Experimental Study on Residual Tumor Angiogenesis after Cryoablation,” Asian Pac J Cancer Prev., 2014, 15(6):2491-2494.
[cited by applicant]
Maor et al., “Irreversible electroporation attenuates neointimal formation after angioplasty,” IEEE Trans Biomed Eng., Sep. 2008, 55(9):2268-2274.
[cited by applicant]
Marx et al., “A comparative study on the structure of
[cited by applicant]
Mi et al., “[Effect of steep pulsed electric fields on the immune response of tumor-bearing Wistar mice],” Sheng Wu Yi Xue Gong Cheng Xue Za Zhi., Apr. 2007, 24(2):253-256, Abstract Only.
[cited by applicant]
Miller et al., “Integrated Carbon Fiber Electrodes within Hollow Polymer Microneedles for Transdermal Electrochemical Sensing.” Biomicrofluidics., Mar. 30, 2011, 5(1):13415.
[cited by applicant]
Miller et al., “Multiplexed microneedle-based biosensor array for characterization of metabolic acidosis,” Talanta., Jan. 15, 2012, 88:739-742.
[cited by applicant]
Milligan et al., “Interstitial Hyperthermia,” Med Instrum., May-Jun. 1984, 18(3):175-180, Abstract Only.
[cited by applicant]
Mishra et al., “Electric Property Sensing Biopsy Needle for Prostate Cancer Detection,” Prostate, Nov. 2013, 73(15):1603-1613.
[cited by applicant]
Morshed et al., “Electrical lysis: dynamics revisited and advances in On-chip operation,” Crit Rev Biomed Eng., 2013, 41(1):37-50.
[cited by applicant]
Neal et al. “In Vitro and Numerical Support for Combinatorial Irreversible Electroporation and Electrochemotherapy Glioma Treatment”, Annals of Biomedical Engineering, Mar. 2014, 42(3):475-487.
[cited by applicant]
Neal et al., “Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice,” PLOS One., May 24, 2013, 8(5):e64559.
[cited by applicant]
Neumann et al., “Permeability changes induced by electric impulses in vesicular membranes,” J Membr Biol., Dec. 29, 1972, 10(3):279-290.
[cited by applicant]
Ninet et al., “Surgical ablation of atrial fibrillation with off-pump, epicardial, high-intensity focused ultrasound: results of a multicenter trial,” The Journal of thoracic and cardiovascular surgery, Sep. 1, 2005, 13…
[cited by applicant]
O'Dowd et al., “An assessment of the effect of pulsed electrical fields on tenderness and selected quality attributes of post rigour beef muscle,” Meat Sci., Feb. 2013, 93(2):303-309.
[cited by applicant]
Onik et al. “Irreversible Electroporation: Implications for Prostate Ablation”, Technology in Cancer Res. and Treatment, Aug. 2007, 6(4): 295-300.
[cited by applicant]
Onik et al. “Long-Term Results of Optimized Focal Therapy for Prostate Cancer: Average 10-Year Follow-Up in 70 Patients,” Journal of Men's Health, Jun. 2014, 11(2):64-74.
[cited by applicant]
Onik et al., “Three-Dimensional Sonographically Monitoring Cryosurgery in a Prostate Phantom,” Journal of Ultrasound, 1996, 16:267-270.
[cited by applicant]
Oshima et al., “Bacterial sterilization and intracellular protein release by a pulsed electric field,” Adv Biochem Eng Biotechnol., Adv Biochem Eng Biotechnol., 2004, 90:113-33.
[cited by applicant]
PCT International Preliminary Report on Patentability in international Appln. No. PCT/US2016/016955, dated Aug. 8, 2017, 6 pages.
[cited by applicant]
PCT International Search Reoprt and Written Opinion in international Appln. No. PCT/US2016/016955, dated Jul. 1, 2016, 9 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in PCT AppIn. No. PCT/US2019/066876, dated Jun. 2, 2020, 11 pages.
[cited by applicant]
Peper et al., “An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells,” J Immunol Methods, Mar. 2014, 405:192-198.
[cited by applicant]
Persson et al., “A model for evaluating therapeutic response of combined cancer treatment modalities: applied to treatment of subcutaneously implanted brain tumors (N32 and N29) in Fischer rats with pulsed electric fiel…
[cited by applicant]
Poudineh et al., “Three-dimensional, sharp-tipped electrodes concentrate applied fields to enable direct electrical release of intact biomarkers from cells,” Lab Chip., May 21, 2014, 14(10):1785-1790.
[cited by applicant]
PRNewswire.com, “Image Guided Cancer Specialists Reports Successful Early Results from Cryoablation and Intra-tumoral Injection of Immunotherapy Drug Combination Yerivoy and Keytruda for the Treatment of Cancer,” Feb. 3…
[cited by applicant]
Ribas et al., “Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.” Clin Cancer Res., Oct. 1, 2019, 15(19):6267-6275.
[cited by applicant]
Royal, et al., “Phase 2 trial of single agent ipilimumab (anti-CLTA-4) for locally advanced or metastatic pancreatic adenocarcinoma,” J. Immunother., 2010, 33(8):828-833.
[cited by applicant]
Sabel et al. “Immunologic Response To Cryoablation Of Breast Cancer,” Breast Cancer Research and Treatment, Mar. 2005, 90(1):97-104.
[cited by applicant]
Sabel et al., “Cryo-Immunology: A review of the literature and proposed mechanisms for stumulatory versus suppressive immune responses,” Cryobiology, 2009, 58:1-11.
[cited by applicant]
Sabel et al., “Effects of high electric fields on micro-organisms. 3. Lysis of erythrocytes and protoplasts,” Biochim Biophys Acta., Aug. 1968, 163(1):37-43.
[cited by applicant]
Schaft et al., “A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes,” Cancer Immunol Immunother., Sep. 2006,55(9):1132-1141.
[cited by applicant]
Shen et al., “Abstract 4746: Modulation of suppressive myeloid populations by tasquinimod,” Cancer Research, Apr. 15, 2013, 73:4746.
[cited by applicant]
Shipman, “Microneedle Sensors May Allow Real-Time Monitoring of Body Chemistry,” Dec. 13, 2011, [retrieved on May 15, 2019] retrieved from URL <https://news.ncsu.edu/2011/12/wmsnarayanmnsensors/>, 3 pages.
[cited by applicant]
Somolinos et al., “Inactivation of
[cited by applicant]
Somolinos et al., “sigB absence decreased Listeria monocytogenes EGD-e heat resistance but not its Pulsed Electric Fields resistance,” Int J Food Microbiol., Jun. 30, 2010, 141(1-2):32-38.
[cited by applicant]
Stevenson et al., “Relationship between cell membrane potential and natural killer cell cytolysis in human hepatocellular carcinoma cells,” Cancer Res., Sep. 1, 1989, 49(17):4842-4845.
[cited by applicant]
Tang et al., “Steep pulsed electric fields modulate cell apoptosis through the change of intracellular calcium concentration,” Colloids Surf B Biointerfaces., Jun. 15, 2007, 57(2):209-214.
[cited by applicant]
Tarek, “Membrane Electroporation: a molecular dynamics Simulation,” Biophys J., 2005, 88:4045-4053.
[cited by applicant]
Traitcheva et al., “Electroporation and alternating current cause membrane permeation of photodynamic cytotoxins yielding necrosis and apoptosis of cancer cells,” Bioelectrochemistry., Oct. 2010, 79(2):257-260.
[cited by applicant]
U.S. Food and Drug Administration, “Kinetics of Microbial Inactivation for Alternative Food Processing Technologies—Pulsed Electric Fields”, A Report of the Institute of Food Technologists for the Food and Drug Administ…
[cited by applicant]
Veiga et al., “Exposure of human leukemic cells to direct electric current: generation of toxic compounds inducing cell death by different mechanisms,” Cell Biochem Biophys., 2005, 42(1):61-74.
[cited by applicant]
Viola et al., “The technology in use for the surgical ablation of atrial fibrillation,” InSeminars in Thoracic and Cardiovascular Surgery, Jul. 1, 2002, 14(3):198-205.
[cited by applicant]
Vora et al., “Interstitial implant with interstitial hyperthermia,” Cancer, Dec. 1, 1982, 50(11):2518-2523.
[cited by applicant]
Waitz et al. “Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy”, Cancer Res., Jan. 2012, 72(2):430-439.
[cited by applicant]
Wikipedia.com [online], “Irreversible Electroporation,” Sep. 8, 2018, retrieved on Sep. 11, 2019, retrieved from URL <https://en.wikipedia.org/wiki/Irreversible_electroporation>, 13 pages.
[cited by applicant]
Williams et al., “Gene therapy approaches to prolonging corneal allograft survival,” Expert Opin Biol Ther., Jul. 2004, 4(7):1059-1071.
[cited by applicant]
Williams, “The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients' Lives,” Gatekeeper Press, Nov. 30, 2019, 115 pages.
[cited by applicant]
Wouters et al., “Membrane permeabilization in relation to inactivation kinetics of
[cited by applicant]
Yuan et al., “Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma,” J Immunother Cancer, Nov. 18, 2013, 1:20.
[cited by applicant]
Zheng et al., “Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells,” J Chromatogr A., Aug. 31, 2007, 1162(2):154-61.
[cited by applicant]
CA Office Action in Canadian Appln. No. 2,932,765, dated Jul. 5, 2022, 7 pages.
[cited by applicant]
CA Office Action in Canadian Appln. No. 2,975,123, dated Feb. 8, 2022, 4 pages.
[cited by applicant]
CA Office Action in Canadian Appln. No. 2,975,123, mailed on Oct. 31, 2023, 4 pages.
[cited by applicant]
Carosella et al., “A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G,” European Urology, Aug. 1, 2015, 68(2):267-79.
[cited by applicant]
Chen et al., “Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model,” International Journal of Hyperthermia, Jan. 1, 20…
[cited by applicant]
CN Office Action in Chinese Appln. No. 201780012169.0, dated Mar. 14, 2022, 11 pages.
[cited by applicant]
EP Office Action in European Appln. No. 16744266.4, mailed on Jun. 23, 2023, 3 pages.
[cited by applicant]
JP Japanese Office Action in Japanese Appln. No. 2018-555838, dated Jan. 24, 2022, 9 pages (with English translation).
[cited by applicant]
KR Office Action in Korean Appln. No. 10-2018-7023079, mailed on Apr. 22, 2024, 9 pages (with English translation).
[cited by applicant]
TW Office Action in Taiwanese Appln. No. 112145372, mailed on Jun. 17, 2024, 32 pages (with English translation).
[cited by applicant]